All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-B7-H3 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human B7-H3. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-B7-H3 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Pancreatic cancer, Breast cancer, Nephroblastoma.
CAR Construction : Fig.1 B7-H3 and PD-L1 expression was detected by flow cytometry following staining with hBRCA84D or anti-PD-L1 antibody or isotype IgG1. Co-expression of B7-H3 and PD-L1 on human tumor cells in vitro and in vivo. Xu, Y., Xiao, Y., Luo, C., Liu, Q., Wei, A., Yang, Y., ... & Wang, Y. (2020). Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. International Immunopharmacology, 84, 106584. |
CAR Construction : Fig.2 Blocking of fusion proteins to PD-L1 was evaluated by competitive ELISA assay in the presence of PD-1-mFc-biotin on plate coated with PD-L1 (n = 2). Fusion proteins simultaneously binds to B7-H3 and PD-L1 and selectively blocks PD-L1 when binding to B7-H3. Xu, Y., Xiao, Y., Luo, C., Liu, Q., Wei, A., Yang, Y., ... & Wang, Y. (2020). Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. International Immunopharmacology, 84, 106584. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-B7-H3 (XR22) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP4175). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION